Electra Therapeutics, Inc. Common stock (ETRA) - Net Assets
Based on the latest financial reports, Electra Therapeutics, Inc. Common stock (ETRA) has net assets worth $-26.77 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($106.50 Million) and total liabilities ($133.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See ETRA net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-26.77 Million |
| % of Total Assets | -25.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Electra Therapeutics, Inc. Common stock - Net Assets Trend (2024–2025)
This chart illustrates how Electra Therapeutics, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. Also explore net asset growth rate of Electra Therapeutics, Inc. Common stock to track the company's year-over-year net asset growth rate.
Annual Net Assets for Electra Therapeutics, Inc. Common stock (2024–2025)
The table below shows the annual net assets of Electra Therapeutics, Inc. Common stock from 2024 to 2025. For live market cap and overall valuation, see ETRA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-30.33 Million | +70.63% |
| 2024-12-31 | $-103.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Electra Therapeutics, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6197500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $142.65 Million | % |
| Total Equity | $-30.33 Million | 100.00% |
Electra Therapeutics, Inc. Common stock Competitors by Market Cap
The table below lists competitors of Electra Therapeutics, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Andes Technology Corp
TW:6533
|
$567.52 Million |
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
$567.57 Million |
|
WCE Holdings Bhd
KLSE:3565
|
$567.59 Million |
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
$567.71 Million |
|
Aris Water Solutions Inc
NYSE:ARIS
|
$567.34 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
$567.32 Million |
|
Eastern Polymer Group Public Company Limited
BK:EPG
|
$567.28 Million |
|
Fujian Minfa Aluminium Co Ltd
SHE:002578
|
$567.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Electra Therapeutics, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -103,261,000 to -30,326,000, a change of 72,935,000.
- Net loss of 61,975,000 reduced equity.
- New share issuances of 91,683,000 increased equity.
- Other factors increased equity by 43,227,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.98 Million | -204.36% |
| Share Issuances | $91.68 Million | +302.32% |
| Other Changes | $43.23 Million | +142.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Electra Therapeutics, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-1.65 | $9.04 | x |
| 2025-12-31 | $-0.48 | $9.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Electra Therapeutics, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.46 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-58.94 Million |
Industry Comparison
This section compares Electra Therapeutics, Inc. Common stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $196,543,967
- Average return on equity (ROE) among peers: -37.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Electra Therapeutics, Inc. Common stock (ETRA) | $-26.77 Million | 0.00% | N/A | $567.41 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $103.64 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $159.22 Million | 44.71% | 0.38x | $282.49 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $154.57 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $836.01 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $7.69 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.41 Billion |
About Electra Therapeutics, Inc. Common stock
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professio… Read more